North America Dominated the Osteoporosis Drugs Market

The size of the osteoporosis drugs market will power at a compound annual growth rate of 5.2% during 2022-2030, to touch a value of USD 22,947 million by 2030.

This growth of the industry is due to increasing healthcare expenditure, the high prevalence of osteoporosis and the speedy urbanization affecting bone health.

India is one of the fastest growing markets for osteoporosis drugs due to deteriorating health of women as a result of morbid lifestyle. Surging number of women suffering from osteoporosis resulted in reduced bone mass and altered bone structure.

The bisphosphonates category marked the largest revenue share of around 30% in the past. Bisphosphonates bind with the surface of the bone’s mineral and effectively block osteoclast-mediated bone resorption. They then embed in the bone and are only released after subsequent resorption resulting in slower rate of bone resorption.

Demand for injectable osteoporosis drugs will grow at highest CAGR. This is due to beneficial features of intravenous drugs like, they do not upset the stomach and it is easier for some individuals to get quarterly or yearly infusion than to take a weekly or monthly pill. 

The osteoporosis drugs market was dominated by North America with a share of around 45%. This is owing to surging geriatric population, increasing cases of obesity, surging lifestyle-related diseases and rising prevalence of osteoporosis.

It is because of the surging prevalence of osteoporosis, increasing requirement for RANK ligand inhibitor, growing demand for injectable drugs and government support, the demand for osteoporosis drugs will continue to rise in the years to come.

Report this Page